Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.

Henry SP, Jagels MA, Hugli TE, Manalili S, Geary RS, Giclas PC, Levin AA.

Nucleic Acid Ther. 2014 Oct;24(5):326-35. doi: 10.1089/nat.2014.0491. Epub 2014 Aug 5.

PMID:
25093529
2.

Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.

Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ.

J Pharmacol Exp Ther. 1997 May;281(2):810-6.

3.

Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.

Henry SP, Beattie G, Yeh G, Chappel A, Giclas P, Mortari A, Jagels MA, Kornbrust DJ, Levin AA.

Int Immunopharmacol. 2002 Nov;2(12):1657-66.

PMID:
12469940
4.

Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.

Shen L, Frazer-Abel A, Reynolds PR, Giclas PC, Chappell A, Pangburn MK, Younis H, Henry SP.

J Pharmacol Exp Ther. 2014 Dec;351(3):709-17. doi: 10.1124/jpet.114.219378. Epub 2014 Oct 9.

5.

Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.

Shen L, Engelhardt JA, Hung G, Yee J, Kikkawa R, Matson J, Tayefeh B, Machemer T, Giclas PC, Henry SP.

Nucleic Acid Ther. 2016 Aug;26(4):236-49. doi: 10.1089/nat.2015.0584. Epub 2016 May 3.

PMID:
27140858
6.
7.

The inhibitory effect of factor J on the alternative complement pathway.

González-Rubio C, Jiménez-Clavero MA, Fontán G, López-Trascasa M.

J Biol Chem. 1994 Oct 21;269(42):26017-24.

PMID:
7929312
8.

Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.

Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA.

Drug Metab Dispos. 2003 Nov;31(11):1419-28.

9.

Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex.

Sheehan JP, Lan HC.

Blood. 1998 Sep 1;92(5):1617-25.

10.

Activation of the alternative pathway of complement by cellulosic hemodialysis membranes.

Cheung AK, Parker CJ, Wilcox L, Janatova J.

Kidney Int. 1989 Aug;36(2):257-65.

11.

Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.

Webb MS, Tortora N, Cremese M, Kozlowska H, Blaquiere M, Devine DV, Kornbrust DJ.

Antisense Nucleic Acid Drug Dev. 2001 Jun;11(3):155-63.

PMID:
11446591
12.

Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.

Leeds JM, Henry SP, Geary R, Burckin T, Levin AA.

Antisense Nucleic Acid Drug Dev. 2000 Dec;10(6):435-41.

PMID:
11198927
13.

A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.

Sartz L, Olin AI, Kristoffersson AC, Ståhl AL, Johansson ME, Westman K, Fremeaux-Bacchi V, Nilsson-Ekdahl K, Karpman D.

J Immunol. 2012 Feb 15;188(4):2030-7. doi: 10.4049/jimmunol.1100319. Epub 2012 Jan 16.

14.

Decay acceleration of the complement alternative pathway C3 convertase.

Hourcade DE, Mitchell LM, Medof ME.

Immunopharmacology. 1999 May;42(1-3):167-73.

PMID:
10408377
16.

Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein.

Hong K, Kinoshita T, Takeda J, Kozono H, Pramoonjago P, Kim YU, Inoue K.

Infect Immun. 1990 Aug;58(8):2535-41.

17.

Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.

Henry SP, Templin MV, Gillett N, Rojko J, Levin AA.

Toxicol Pathol. 1999 Jan-Feb;27(1):95-100. Review.

PMID:
10367680
18.

Human factor H-related protein 2 (CFHR2) regulates complement activation.

Eberhardt HU, Buhlmann D, Hortschansky P, Chen Q, Böhm S, Kemper MJ, Wallich R, Hartmann A, Hallström T, Zipfel PF, Skerka C.

PLoS One. 2013 Nov 18;8(11):e78617. doi: 10.1371/journal.pone.0078617. eCollection 2013.

20.

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.

Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.

Aliment Pharmacol Ther. 2002 Oct;16(10):1761-70.

Supplemental Content

Support Center